Delcath Systems Inc. has announced the publication of a retrospective analysis conducted by researchers at the University of Tubingen, Germany, evaluating the outcomes of liver-directed therapies in patients with metastatic uveal melanoma (mUM) and liver metastases. The study, published in the International Journal of Cancer, highlights the potential benefits of early use of chemosaturation therapy-also known as percutaneous hepatic perfusion (PHP)-using Delcath's CHEMOSAT® Hepatic Delivery System, which utilizes the same technology as the FDA-approved HEPZATO KIT™. Results from the analysis indicate that PHP, when used as a first-line liver-directed therapy, achieved a 100% disease control rate and was associated with improved melanoma-specific survival compared to systemic therapies. Previous related data from this research group were presented at the European Association of Dermato-Oncology (EADO) Congress in April 2025.